Citigroup Inc Viking Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 98,388 shares of VKTX stock, worth $6.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,388

Previous 214,071 54.04%

Holding current value

$6.77 Million

Previous $17.6 Million 70.29%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$47.39 - $80.2 $5.48 Million - $9.28 Million	-115,683 Reduced 54.04%	98,388 $5.22 Million
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $613,315 - $3.33 Million	35,248 Added 19.71%	214,071 $17.6 Million
Q4 2023 Feb 09, 2024	SELL	$9.24 - $19.64 $1.67 Million - $3.55 Million	-180,762 Reduced 50.27%	178,823 $3.33 Million
Q3 2023 Nov 09, 2023	BUY	$10.92 - $16.0 $2.09 Million - $3.07 Million	191,826 Added 114.35%	359,585 $3.98 Million
Q2 2023 Aug 10, 2023	SELL	$14.84 - $24.79 $5.82 Million - $9.72 Million	-391,982 Reduced 70.03%	167,759 $2.72 Million
Q1 2023 May 11, 2023	BUY	$8.08 - $17.33 $3.49 Million - $7.48 Million	431,531 Added 336.58%	559,741 $9.32 Million
Q4 2022 Feb 09, 2023	BUY	$2.72 - $9.4 $333,964 - $1.15 Million	122,781 Added 2261.58%	128,210 $1.21 Million
Q3 2022 Nov 10, 2022	BUY	$2.55 - $3.89 $11,388 - $17,372	4,466 Added 463.76%	5,429 $15,000
Q2 2022 Aug 10, 2022	SELL	$2.11 - $3.15 $8,916 - $13,311	-4,226 Reduced 81.44%	963 $3,000
Q1 2022 May 12, 2022	SELL	$3.0 - $4.88 $549,810 - $894,357	-183,270 Reduced 97.25%	5,189 $16,000
Q4 2021 Feb 10, 2022	BUY	$4.6 - $6.72 $434,078 - $634,132	94,365 Added 100.29%	188,459 $867,000
Q3 2021 Nov 10, 2021	BUY	$5.58 - $7.04 $525,044 - $662,421	94,094 New	94,094 $591,000

Others Institutions Holding VKTX

# of Institutions

478

Shares Held

66.1M

Call Options Held

6.24M

Put Options Held

3.01M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.28B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account